nivolumab
Selected indexed studies
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. (Lancet, 2025) [PMID:39874977]
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. (Cell, 2017) [PMID:29033130]
- Nivolumab Plus Relatlimab: First Approval. (Drugs, 2022) [PMID:35543970]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) pubmed
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. (2025) pubmed
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. (2017) pubmed
- Nivolumab Plus Relatlimab: First Approval. (2022) pubmed
- Relatlimab-nivolumab: A practical overview for dermatologists. (2023) pubmed
- Nivolumab for the treatment of hepatocellular carcinoma. (2020) pubmed
- Nivolumab for the treatment of unresectable pleural mesothelioma. (2020) pubmed
- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. (2022) pubmed
- Nivolumab for the treatment of hepatocellular carcinoma. (2018) pubmed
- Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib. (2021) pubmed